Superior Planning, LLC’s Madrigal Pharmaceuticals MDGL Stock Holding History

Superior Planning, LLC’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.02K	Buy	+4	New	+$2.11K	﹤0.01%	1558

Other funds holding MDGL

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

Superior Planning, LLC's MDGL Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 4 shares worth $2.02K. The stake represents ﹤0.01% of the portfolio and ranks #1558 among its holdings.

278 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Superior Planning, LLC held 4 shares of Madrigal Pharmaceuticals worth $2.02K as of Q3 2026.
Madrigal Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1558 holding.
278 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.